RYR1 and neoplasm: The median OS was 438 (95% CI, 334 to 496) days among patients with low tumor CcO activity and 420 (95% CI, 295 to 586) days among patients with high tumor CcO activity (P = .84 by log-rank test) (Figure 1C).